The single small trial reported symptom improvement in approximately 60% of participants (pain reduction, fatigue improvement, better sleep), but without a placebo control or sham-injection group, attribution of benefit to the cell therapy versus natural fluctuation or expectancy is impossible. Real-world success rates remain unknown.
Only 1 completed trial and 0 actively recruiting trials are registered specifically for fibromyalgia cell therapy, reflecting the early, exploratory stage of this application. That single published study involved placental MSC infusion in a small cohort (n≈20–30) and reported modest improvements in pain scores (average 20–30% reduction on visual analogue pain scale) and some improvement in fatigue severity. Biochemical markers of inflammation (IL-6, TNF-α) showed trending reductions. No control arm was present, and long-term follow-up was not reported.
Am I a candidate? → · Fibromyalgia & Chronic Fatigue: full overview → · Fibromyalgia & Chronic Fatigue cost → · Cost →
Medically reviewed by StemCellAtlas’s editorial team with Kiian Nadiia, MD, PhD (Paediatric Neurologist · Medical Director, CSM Clinic Network · 12+ yrs in Autism Spectrum Disorders) of partner clinic Stem Plus (Sofia), against ISSCR, FDA & EMA guidance. Educational information, not medical advice; figures indicative.
Medicina rigenerativa certificata GMP nel cuore dell'UE — da 3.000–8.000 €, una frazione dei prezzi USA o tedeschi. Protocolli personalizzati per pazienti da oltre 50 Paesi.
Valutazione medica gratuita